Literature DB >> 23801160

[Histopathology of renal cell carcinoma].

C G Stöhr1, K Amann, A Hartmann.   

Abstract

By integrating genetic data into the traditional histology and immunohistochemistry-based classification system, the revised WHO classification of malignant tumors (2004) defined additional renal cell carcinoma subtypes, thereby enabling the application of additional diagnostic procedures.

Entities:  

Mesh：

Year:  2013        PMID： 23801160     DOI： 10.1007/s00120-013-3223-4

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  12 in total

1.  Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status.

Authors:  Chiara Bardella; Mona El-Bahrawy; Norma Frizzell; Julie Adam; Nicola Ternette; Emine Hatipoglu; Kimberley Howarth; Linda O'Flaherty; Ian Roberts; Gareth Turner; Jennifer Taylor; Konstantinos Giaslakiotis; Valentine M Macaulay; Adrian L Harris; Ashish Chandra; Heli J Lehtonen; Virpi Launonen; Lauri A Aaltonen; Christopher W Pugh; Radu Mihai; David Trudgian; Benedikt Kessler; John W Baynes; Peter J Ratcliffe; Ian P Tomlinson; Patrick J Pollard
Journal:  J Pathol       Date:  2011-06-01       Impact factor: 7.996

2.  An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma.

Authors:  Aikseng Ooi; Jing-Chii Wong; David Petillo; Douglas Roossien; Victoria Perrier-Trudova; Douglas Whitten; Bernice Wong Hui Min; Min-Han Tan; Zhongfa Zhang; Ximing J Yang; Ming Zhou; Betty Gardie; Vincent Molinié; Stéphane Richard; Puay Hoon Tan; Bin Tean Teh; Kyle A Furge
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

Review 3.  Targeting the c-Met signaling pathway in cancer.

Authors:  Benedetta Peruzzi; Donald P Bottaro
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

4.  Renal cell carcinoma guideline.

Authors:  Börje Ljungberg; Damian C Hanbury; Marcus A Kuczyk; Axel S Merseburger; Peter F A Mulders; Jean-Jacques Patard; Ioanel C Sinescu
Journal:  Eur Urol       Date:  2007-03-28       Impact factor: 20.096

Review 5.  Renal cell carcinoma: current status and emerging therapies.

Authors:  Eric C Nelson; Christopher P Evans; Primo N Lara
Journal:  Cancer Treat Rev       Date:  2007-02-27       Impact factor: 12.111

6.  Usefulness of a break-apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma.

Authors:  Soo Hee Kim; Yoomi Choi; Hae Yeon Jeong; Kyoungbun Lee; Ji Youn Chae; Kyung Chul Moon
Journal:  Virchows Arch       Date:  2011-07-20       Impact factor: 4.064

7.  Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method.

Authors:  Emiko Sugawara; Yuki Togashi; Naoto Kuroda; Seiji Sakata; Satoko Hatano; Reimi Asaka; Takeshi Yuasa; Junji Yonese; Masanobu Kitagawa; Hiroyuki Mano; Yuichi Ishikawa; Kengo Takeuchi
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860

8.  TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.

Authors:  Qiu Rao; Sean R Williamson; Shaobo Zhang; John N Eble; David J Grignon; Mingsheng Wang; Xiao-Jun Zhou; Wenbin Huang; Puay-Hoon Tan; Gregory T Maclennan; Liang Cheng
Journal:  Am J Surg Pathol       Date:  2013-06       Impact factor: 6.394

9.  Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.

Authors:  G Martignoni; M Pea; S Gobbo; M Brunelli; F Bonetti; D Segala; Chin-Chen Pan; G Netto; C Doglioni; O Hes; P Argani; M Chilosi
Journal:  Mod Pathol       Date:  2009-04-24       Impact factor: 7.842

10.  [Renal cell carcinoma 2008. Histopathology, molecular genetics and new therapeutic options].

Authors:  C G Hammerschmied; B Walter; A Hartmann
Journal:  Pathologe       Date:  2008-09       Impact factor: 1.011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.